Latest Breaking News On - Emalex biosciences - Page 1 : comparemela.com

Royalty Pharma : Q1 2024 Press Release - MarketScreener

Royalty Pharma : Q1 2024 Press Release - MarketScreener
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesRoche evrysdiPablo legorretaCabometyx cometriqTremfya crohnJohnson imbruvicaEmalex biosciencesNovarti promactaJohnson tremfyaAstellas pharmaBristol myersEuropean commissionEuropean medicines agencyTeva pharmaceuticalsExchange commissionBristol myers squibb

Royalty Pharma Reports First Quarter 2024 Results - Royalty Pharma (NASDAQ:RPRX)

Royalty Pharma Reports First Quarter 2024 Results - Royalty Pharma (NASDAQ:RPRX)
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United statesJohnson tremfyaEmalex biosciencesNovarti promactaTremfya crohnRoche evrysdiPablo legorretaJohnson imbruvicaExchange commissionPortfolio receiptsRoyalty pharmaChief executiveRoyalty receiptsPortfolio cash flowCash flowCapital deployment

Royalty Pharma Reports Q4 and Full Year 2023 Results

Royalty Pharma Reports Q4 and Full Year 2023 Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesEmalex biosciencesFarxiga onglyzaCabometyx cometriqRoche evrysdiPablo legorretaJohnson imbruvicaJohnson tremfyaAscendis pharmaNovarti promactaDrug administrationEuropean commissionTeva pharmaceuticals industries ltdTherapeutics incBristol myers squibbExchange commission

Emalex Biosciences Releases Results of 12-Month Open-Label Extension Study for Tourette Syndrome Candidate

Emalex Biosciences Releases Results of 12-Month Open-Label Extension Study for Tourette Syndrome Candidate
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

British columbiaUnited statesFrederick munschauerEmalex biosciencesInternational congressChild neurology society annual meetingParagon biosciencesMovement disorder societyNorth americaOrphan drugFast track

Emalex Biosciences Releases Results of 12-Month Open-Label Extension Study for Tourette Syndrome Can

Long-term safety data collected in pediatric patients treated with investigational drug ecopipam; durable treatment effect reported with no evidence of tachyphylaxisCHICAGO (BUSINESS WIRE) An open-label extension study of 121 pediatric patients with Tourette syndrome evaluated the safety profile of the investigati.

United statesBritish columbiaFrederick munschauerEmalex biosciencesInternational congressMovement disorder societyChild neurology society annual meetingParagon biosciencesNorth americaOrphan drugFast track